A sweeping new examination of opioid medications has delivered an uncomfortable verdict for prescribers: the drugs that doctors routinely reach for to treat acute pain often barely outperform placebos and deliver relief for only hours, not days.
Researchers at the University of Sydney conducted the most comprehensive analysis to date, sifting through 59 systematic reviews covering more than 50 acute pain conditions in both children and adults. The work examined common opioids including codeine, morphine, oxycodone, and tramadol, and was published in the journal Drugs.
The findings challenge a entrenched assumption in medicine: that opioids represent the gold standard first move in acute pain management.
"Opioids did not provide large or lasting pain relief compared with placebo for the vast majority of acute pain conditions," said Associate Professor Christina Abdel Shaheed, the study's lead author. "Pain relief typically lasted only a few hours."
The research revealed a more nuanced picture. For certain conditions, opioids showed modest short-term benefit. These included abdominal pain, post-dental surgery pain, ear procedure discomfort, traumatic limb injuries, childbirth, caesarean delivery, and bunion removal.
But in many other areas, they flopped. Patients with kidney stone pain, post-tonsillectomy discomfort, some types of limb surgery pain, and newborns on assisted breathing devices saw no meaningful advantage from opioids over placebo. Results were inconsistent for cardiac pain, post-hysterectomy pain, and topical opioid patches used for skin conditions.
Particularly troubling was the performance in acute musculoskeletal pain, one of the most common reasons doctors prescribe these drugs. Oral opioids proved only marginally better than placebo in the first six to 48 hours and came with elevated risk of side effects like nausea and vomiting.
The safety picture extends beyond immediate side effects. Opioid dependence can emerge quickly, sometimes within days of first use, and regular use for acute pain creates pathways to tolerance, addiction, overdose, and death.
Dr. Stephanie Mathieson, a co-first author, flagged another concern: clinical trials often failed to adequately document adverse effects, meaning the true harm profile may be worse than reported literature suggests.
The authors emphasized that patients deserve transparency about these risks and that doctors should prescribe opioids at the lowest effective dose for the shortest possible duration when acute pain calls for them at all.
Associate Professor Joshua Zadro noted the broad relevance of the work. "These findings matter for patients across all age groups experiencing acute pain, the doctors treating them, and policymakers regulating these medicines."
Author Jessica Williams: "The evidence is now too large to ignore: we've built an entire system around opioids for pain that the science says we shouldn't trust."
Comments